Personalis (NASDAQ:PSNL) Cut to “Strong Sell” at Zacks Research

Personalis (NASDAQ:PSNL) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th. TD Cowen reiterated a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Needham & Company LLC cut shares of Personalis from a “buy” rating to a “hold” rating in a report on Monday. Lake Street Capital downgraded shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a research report on Monday. Finally, BTIG Research upped their target price on shares of Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a report on Monday. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $14.25.

Personalis Price Performance

Personalis stock opened at $12.47 on Tuesday. The stock has a market cap of $1.31 billion, a PE ratio of -12.23 and a beta of 2.24. The stock’s fifty day moving average is $11.36 and its two-hundred day moving average is $9.01. Personalis has a 1-year low of $3.84 and a 1-year high of $16.39.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.48 million. On average, research analysts expect that Personalis will post -1.07 earnings per share for the current fiscal year.

Insider Transactions at Personalis

In other news, CFO Aaron Tachibana sold 4,982 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the completion of the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,783,662. The trade was a 2.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,558,668.88. The trade was a 29.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock worth $5,599,929 in the last quarter. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Personalis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. boosted its stake in Personalis by 273.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after purchasing an additional 7,896,714 shares during the period. Price T Rowe Associates Inc. MD grew its position in Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after purchasing an additional 1,347,439 shares during the last quarter. Kennedy Capital Management LLC increased its stake in Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after purchasing an additional 1,281,695 shares during the period. Aberdeen Group plc increased its stake in Personalis by 36.1% in the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after purchasing an additional 861,948 shares during the period. Finally, Next Century Growth Investors LLC purchased a new stake in shares of Personalis in the fourth quarter valued at about $4,970,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.